SMA therapy Isembyl approved, $205M of cash raised upon sale of PRV

Scholar Rock reported Q3 2026 results noting the September FDA approval of Isembyl for SMA, alongside a $205M deal to sell a Priority Review Voucher. The company is building on early commercial demand while advancing regulatory applications in Japan and Europe.